Loading
A phase 1/2 trial of Purinostat in advanced solid tumours, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06431243 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 132 participants planned, started 2024-05-08 and due to reach its primary completion in 2026-05-01. Interventions recorded: A0/B0 group Purinostat Mesylate 11.2mg/m2, A0/B0 group Purinostat Mesylate 15mg/m2, A group Purinostat Mesylate 6mg/m2, A group Purinostat Mesylate 8.4mg/m2, A group Purinostat Mesylate 11.2mg/m2 and A group Purinostat Mesylate 15 mg/m2.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.